Clinical trials: Hepatic Malignancies
Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard Treatments
Hepatic Artery Transfusion of NKG2D CAR-NK Cells Followed by Intravenous Infusion of NKG2D CAR-T Cells to Treat Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard Treatments: a Phase I Exploratory Clinical Trial
This is a single-center, single-arm, open-label, dose-escalation clinical study to evaluate the safety and preliminary efficacy of NKG2D CAR-NK cells followed by NKG2D CAR-T cells in patients with advanced solid tumors…
- Trial name
- NCT07021534
- Testing
- NKG2D CAR NK and NKG2D CAR T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Zhejiang University
Hepatic Cancer, Metastatic Cancer
Prevention and Treatment of Complications of Endovascular Methods in Patients With Malignant Liver Tumors
In the structure of malignant liver lesions, two main groups are distinguished - primary liver cancer and metastatic liver damage. The five-year survival rate of patients with malignant liver tumors does not exceed 6%.
- Conditions
- Hepatic Cancer, Metastatic Cancer, Chemotherapy Effect
- Trial name
- PATOC (NCT04764409)
- Testing
- Chemoembolization, Chemoinfusion
- Where
- Russia
- Volunteers
- 500 people
- Sponsor
- Central Clinical Hospital RZD-Medicine, Russian Federation
Uveal Melanoma, Liver Metastases
Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
Patients with uveal melanoma metastatic to the liver will be treated with embolization of the hepatic artery every 4 weeks. GM-CSF (granulocyte-macrophage colony simulating factor) or normal saline will be injected into one of…
- Trial name
- NCT00661622
- Testing
- GM-CSF, Embolization
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hepatic Tumor
Multicenter Study to Evaluate a New Robotic Device for Image-guided Percutaneous Needle Placement
This study evaluates the safety and performance of a new robotic device in the treatment of hepatic thermoablation in adults. The new robotic device will be used in all patients.
- Trial name
- NCT04230642
- Testing
- The Quantum Surgical device
- Where
- 2 sites in France
- Volunteers
- 22 people
- Sponsor
- Quantum Surgical
Advanced Malignancies
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.
The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal hepatic function and participants with hepatic impairment.
- Trial name
- NCT04831944
- Testing
- parsaclisib
- Where
- 5 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Systemic Fungal Infections
Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents
This multicenter observational cohort study proposes to establish the risks of short and long-term outcomes in users of parenteral micafungin and in users of other parenteral antifungal agents from 2005 through 2012 with…
- Trial name
- MYCOS (NCT01686607)
- Testing
- Parenteral micafungin application, Other parenteral antifungal drugs
- Where
- 6 sites in United States
- Volunteers
- 40,110 people
- Sponsor
- Astellas Pharma Europe B.V.
Hepatocellular Carcinoma
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
This is a single-arm, exploratory study to evaluate the efficacy and safety of HAIC in combination with sintilimab and bevacizumab in the first line treatment of patients with BCLC-C hepatocellular carcinoma.
- Trial name
- NCT05617430
- Testing
- HAIC, Sintilimab, Bevacizumab Biosimilar IBI305
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hepatocellular Carcinoma
Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma
This is a single-center, single-arm, phase II clinical study, to explore the efficacy and safety of modified TOMOX-HAIC combined with sintilimab and bevacizumab biosimilar as first line treatment in patients with advanced…
- Trial name
- NCT06285019
- Testing
- TOMOX-HAIC, Sintilimab, Bevacizumab
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Fudan University
Hepatic Insufficiency
Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects
This is an open-label study to evaluate the pharmacokinetics, safety and tolerability of single oral doses of Alisporivir in subjects with mild and moderate hepatic impairment compared to matched healthy subjects with normal…
- Trial name
- NCT01860326
- Testing
- Alisporivir
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Debiopharm International SA
Multiple Myeloma
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment
The goal of the clinical trial is to collect safety data and information on how the body processes BVd in people with multiple myeloma (MM) who have moderate liver problems, compared with similar participants who have normal…
- Trial name
- NCT07609706
- Testing
- Belantamab mafodotin, Bortezomib, Dexamethasone
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Liver Transplant; Complications, Ischemia Reperfusion Injury
Abdominal Regional Perfusion in Donation After Cardiac Death for Multi-Organ Transplantation
The main purpose of this study is to increase the pool of organs available for donation by performing ARP to recondition donation after cardiac death (DCD) organs prior to transplantation.
- Conditions
- Liver Transplant; Complications, Ischemia Reperfusion Injury, Cirrhosis, Liver Cancer
- Trial name
- NCT03946852
- Testing
- Abdominal Regional Perfusion
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre
Biliary Tract Cancer (BTC)
HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer
Biliary tract cancer (BTC), including cholangiocarcinoma and gallbladder cancer (GBC), is a group of malignancies with highly heterogeneous, highly aggressiveness, and poor prognosis.
- Trial name
- NCT07466238
- Testing
- HAIC(GOLF), Bevacizumab, PD-1/PD-L1 inhibitor
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Peking University
HCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy
HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with high tumor burden advanced-stage hepatocellular…
- Conditions
- HCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy, BCLC Stage C Hepatocellular Carcinoma, Lenvatinib
- Trial name
- NCT06631326
- Testing
- hepatic artery infusion chemotherapy, Lenvatinib + PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 244 people
- Sponsor
- First Hospital of China Medical University
Hepatocellular Carcinoma
PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer
This is a multicenter, randomized, positive parallel controlled clinical study to evaluate the short-term and long-term efficacy and safety of PVL/PVE combined with DEB-TACE in the treatment of unresectable patients with large or…
- Trial name
- CCGLC-004 (NCT05103007)
- Testing
- DEB-TACE, PVL/PVE+DEB-TACE
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tongji Hospital
Hepatic Hemangioma, Liver Cancer
Application of Perioperative Remote Ischemic Conditioning in Patients Undergoing Hepatectomy
Our primary aim is to investigate whether perioperative remote ischemic conditioning (PRIC) as an adjunctive treatment can improve postoperative recovery in patients undergoing hepatectomy as an adjunct to standard treatment.
- Conditions
- Hepatic Hemangioma, Liver Cancer, Hepatolithiasis, Hepatectomy
- Trial name
- NCT06130436
- Testing
- Remote Ischemic Conditioning Once Daily, Remote Ischemic Conditioning Twice Daily
- Where
- China
- Volunteers
- 135 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Carcinoma, Hepatocellular, Liver Neoplasms
HR Versus RFA for HCC in Patients With PHT
The purpose of the investigators' study is to prospectively compare the safety and efficacy of hepatic resection to radiofrequency ablation for hepatocellular carcinoma in patients with portal hypertension.
- Conditions
- Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Glandular and Epithelial
- Trial name
- HR-HCC/PHT (NCT02192671)
- Testing
- Hepatic Resection, Radiofrequency Ablation
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma
Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.
This study is a single-center, open-label Phase II clinical trial, aiming to enroll approximately 30 unresectable BCLC stage B or C hepatocellular carcinoma (HCC) patients from China.
- Trial name
- NCT06375486
- Testing
- Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Liver Cancer
Measurement of Pro-angiogenic Markers in Patients With Hepatic Metastases Undergoing SIRT
This study is being done to investigate the influence of giving radiation to the liver on tumors involving the liver. Investigator is specifically looking at this effect on the blood vessels within the tumor.
- Trial name
- NCT00994370
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Rutgers, The State University of New Jersey
Hepatocellular Carcinoma(HCC), Cirrhotic Portal Hypertension
Optimal Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal Hypertension
There is no consensus about the optimal treatment of hepatocellular carcinoma (HCC) with cirrhotic portal hypertension, While this group of patients are classified as hepatectomy contraindication according to guidelines from…
- Trial name
- NCT01642446
- Testing
- Precise hepatectomy, Combined intervention (chemoembolization/ablation)
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer, Liver Metastasis
Surgical Recovery After Left Lateral Hepatic Sectionectomy: Laparoscopic Versus Open Surgery.
The ORANGE II trial is a double blinded randomised controlled trial that will provide evidence on the merits of laparoscopic surgery in patients undergoing a left lateral hepatic sectionectomy in terms of time to functional…
- Conditions
- Colorectal Cancer, Liver Metastasis, Liver Disease
- Trial name
- ORANGE II (NCT00874224)
- Testing
- laparoscopic left lateral hepatic sectionectomy, open left lateral hepatic sectionectomy
- Where
- Netherlands
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.